| 7-May-2012 |
Unigene Announces First Quarter 2012 Financial Results |
| 3-Apr-2012 |
Unigene’s Proprietary Oral Peptide Delivery Platform is Further Validated with Cara Therapeutics’ Successful Completion of its Phase 1 Study Using Unigene’s Oral Formulation of Novel Kappa Opioid Receptor Agonist, CR845 |
| 2-Apr-2012 |
UNIGENE APPOINTS JACK WYSZOMIERSKI TO ITS BOARD OF DIRECTORS |
| 29-Mar-2012 |
UNIGENE TO PRESENT AT THE 11TH ANNUAL NEEDHAM HEALTHCARE CONFERENCE |
| 22-Mar-2012 |
SUPREME COURT DENIES APOTEX’S PETITION FOR A WRIT OF CERTIORARI |
| 15-Mar-2012 |
UNIGENE APPOINTS DAVID MOSKOWITZ AS CHIEF FINANCIAL OFFICER |
| 8-Mar-2012 |
Unigene Announces Fourth Quarter and Full-Year 2011 Results |
| 5-Mar-2012 |
UNIGENE’S PROPRIETARY PEPTELLIGENCE™ PLATFORM SELECTED BY STEALTH PEPTIDES FOR AN ORAL PHASE 1 CLINICAL STUDY |
| 1-Mar-2012 |
Unigene to Announce Fourth Quarter and Full-Year 2011 Financial Results on March 8, 2012 |
| 27-Feb-2012 |
Unigene to Present at IBC’s 4th Annual AsiaTIDES Oligonucleotide and Peptide® Conference |
| 8-Feb-2012 |
UNIGENE ANNOUNCES KEY APPOINTMENTS AS BIOTECHNOLOGIES STRATEGIC BUSINESS UNIT CONTINUES TO GROW IN 2012 |
| 7-Feb-2012 |
Unigene to Present at the 14th Annual BIO CEO & Investor Conference on |
| 1-Feb-2012 |
UNIGENE RECEIVES 2012 DRUG DELIVERY PARTNERSHIPS INDUSTRY ACHIEVEMENT AWARD |
| 12-Jan-2012 |
Unigene Laboratories Granted US Patent for Peptide-Based Technology for Treatment of Obesity |
| 9-Jan-2012 |
UNIGENE PROVIDES 2012 BUSINESS OUTLOOK |
| 4-Jan-2012 |
Unigene to Present at Biotech Showcase™ 2012 in San Francisco on January 9 |
| 19-Dec-2011 |
UNIGENE’S 2011 YEAR IN REVIEW – KEY ELEMENTS IN PLACE TO ADDRESS DEBT IN 2012 |
| 7-Dec-2011 |
Unigene to Present at the Oppenheimer 22nd Annual Healthcare Conference on December 13, 2011 |
| 5-Dec-2011 |
Unigene Regains Exclusive Worldwide Rights of Oral PTH from GSK |
| 30-Nov-2011 |
Unigene’s Proprietary Peptelligence™ Platform used to Commence Cara Therapeutics Phase 1 Clinical Trial of Oral Novel Peripherally-Acting Kappa Opioid Agonist |
| 16-Nov-2011 |
Unigene Strengthens Board with the Appointment of Walgreen’s Executive, Thomas J. Sabatino, Jr.-Board strengthened with extensive healthcare and legal expertise- |
| 14-Nov-2011 |
Unigene Announces Novartis’ Disclosure of First Interpretable Results from Phase 3 Trial of Calcitonin (SMC021) in the Treatment of Post-menopausal Osteoporosis |
| 10-Nov-2011 |
Unigene to Present at the Lazard Capital Markets 8th Annual Healthcare Conference on November 16, 2011 |
| 9-Nov-2011 |
Unigene Announces Positive Top-Line Results of Phase 2 Oral PTH Study for the Treatment of Osteoporosis in Postmenopausal Women |
| 9-Nov-2011 |
Unigene Reports Third Quarter 2011 Financial Results |
| 7-Nov-2011 |
Unigene to Announce Third Quarter 2011 Financial Results on November 9, 2011 |
| 20-Oct-2011 |
Unigene Completes All Patient Dosing in Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women |
| 20-Oct-2011 |
Unigene to Present at the 10th Annual BIO Investor Forum on October 25, 2011 |
| 6-Oct-2011 |
Unigene and Nordic Bioscience Combine Industry Leading Capabilities to Advance Unigene’s Proprietary Peptides through Phase 2 Proof-of-Concept for the Treatment of Type 2 Diabetes, Osteoarthritis and Osteoporosis |
| 6-Oct-2011 |
Unigene’s Leading Peptide Development Expertise Endorsed with Strategic Equity Investment of up to $6 Million by Industry Legend Dr. Claus Christiansen |
| 6-Oct-2011 |
Unigene to Host Live Conference Call and Webcast to Discuss Collaboration with Nordic Bioscience and Formation of Joint Development Vehicle |
| 21-Sep-2011 |
Unigene Divests Non-Core Asset and Focuses Resources on High Valuation Drug Development and Peptide Drug Delivery Opportunities – Assigns Site Directed Bone Growth Patent Portfolio to Leading Researcher |
| 19-Sep-2011 |
Unigene’s Industry Leading, Proprietary Oral Delivery and Recombinant Manufacturing Technology Platforms are Further Validated with Positive Phase 3 Safety and Efficacy Data for OSTORA(TM) |
| 8-Sep-2011 |
Unigene to Present at the Rodman & Renshaw Annual Global Investment Conference on September 12, 2011 |
| 7-Sep-2011 |
Unigene Appoints Industry Veteran Theron (Ted) Odlaug as New Independent Director to Board |
| 30-Aug-2011 |
Unigene Successfully Defends its Robust Intellectual Property Portfolio |
| 8-Aug-2011 |
Unigene Reports Second Quarter 2011 Financial Results |
| 8-Aug-2011 |
Unigene and GSK Enter Development Services and Clinical Supply Agreement in Preparation of Potential Phase 3 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women |
| 4-Aug-2011 |
Unigene to Present at the 2011 Canaccord Genuity Growth Conference on August 9, 2011 |
| 2-Aug-2011 |
Unigene to Announce Second Quarter 2011 Financial Results on August 8, 2011 |
| 27-Jun-2011 |
Unigene Presents Positive Advanced Preclinical Data for UGP281 a Potent, Orally Delivered Anorexigenic Peptide in a Late-Breaking Poster Presentation at the American Diabetes Association 71st Scientific Sessions |
| 13-Jun-2011 |
Unigene Continues Solid Execution of Focused Turnaround Strategy and Monetizes Non-Core Asset with the Termination of China Joint Venture |
| 19-May-2011 |
Unigene Announces Manufacturing and Clinical Supply Agreement with Cara Therapeutics for Phase 1 Study of Novel Kappa Receptor Agonist |
| 17-May-2011 |
Unigene Announces Presentations on Proprietary Recombinant Production and Oral Peptide Drug Delivery Technology at Upcoming 2011 TIDES Summit |
| 9-May-2011 |
Unigene Reports First Quarter 2011 Financial Results |
| 3-May-2011 |
Unigene to Announce First Quarter 2011 Financial Results on May 9, 2011 |
| 27-Apr-2011 |
Unigene Completes Patient Enrollment of Oral PTH Phase 2 Study for the Treatment of Osteoporosis in Postmenopausal Women |
| 13-Apr-2011 |
Unigene Increases Support for Tarsa in Preparation for Oral Calcitonin NDA Submission |
| 24-Mar-2011 |
Unigene’s Oral Peptide Drug Delivery Technology Validated with Positive Top-Line Phase 3 Results from Tarsa’s ORACAL Trial of Oral Calcitonin |
| 15-Mar-2011 |
Unigene Doses First Patient in Phase 2 Oral PTH Study for the Treatment of Osteoporosis in Postmenopausal Women |
| 10-Mar-2011 |
Unigene Reports Fourth Quarter and Full Year 2010 Financial Results |
| 9-Mar-2011 |
Unigene to Present at the ROTH 23rd Annual OC Growth Stock Conference on March 15, 2011 |
| 3-Mar-2011 |
Unigene to Announce Fourth Quarter and Full Year 2010 Financial Results on March 10, 2011 |
| 24-Feb-2011 |
Unigene Accelerates the Development of its Lead Proprietary Anorexigenic Peptide UGP281 for Obesity |
| 23-Feb-2011 |
Unigene to Present at the 9th Annual BioPartnering North America(TM) Conference on March 1, 2011 |
| 7-Feb-2011 |
Unigene to Present at the 13th Annual BIO CEO and Investor Conference on February 14, 2011 |
| 10-Jan-2011 |
Unigene Provides 2011 Business Outlook |
| 10-Dec-2010 |
Unigene to Advance Phase 2 Development of Oral PTH Program by Entering into an Amended and Restated Exclusive Worldwide License Agreement with GSK |
| 23-Nov-2010 |
Unigene Completes Executive Management Team and Names Jenene D. Thomas, VP of Investor Relations and Corporate Communications |
| 9-Nov-2010 |
Unigene Announces Financial Results for Third Quarter 2010 and Highlights the Momentum of Its New Corporate Strategy |
| 8-Nov-2010 |
Webcast Alert: Unigene Laboratories, Inc. (UGNE) Announces Third Quarter 2010 Earnings Conference Call |
| 4-Nov-2010 |
Unigene to Release Third Quarter 2010 Results and Host Conference Call |
| 2-Nov-2010 |
Unigene Names Alex Martin VP Business Development and Head of Commercial Operations |
| 21-Oct-2010 |
Unigene Reports Top-Level Results on Phase III Study of Oral Calcitonin in Osteoarthritis Patients |
| 4-Oct-2010 |
Unigene Bolsters Leadership Team with Two Key Appointments |
| 28-Sep-2010 |
Unigene Expands Board of Directors; Elects Joel A. Tune as Director |
| 24-Sep-2010 |
Tarsa Therapeutics And Unigene Present Preclinical Data Suggesting Calcitonnin May Have Utility In Combination Therapy For The Treatment Of Osteoarthritis |
| 14-Sep-2010 |
Unigene CEO Presents New Strategy and Corporate Realignment at Rodman & Renshaw 12th Annual Healthcare Conference |
| 8-Sep-2010 |
Unigene to Present at the Rodman & Renshaw 12th Annual Healthcare Conference |
| 9-Aug-2010 |
Unigene Announces Financial Results For Second Quarter 2010 |
| 27-Jul-2010 |
Unigene to Release Second Quarter 2010 Results and Host Conference Call |
| 23-Jul-2010 |
Unigene Reports Continuation of Phase III Study of Oral Calcitonin in Osteoarthritis Patients |
| 23-Jul-2010 |
Unigene Notes Progress of Tarsa’s Phase III ORACAL Trial of its Oral Calcitonin for the Treatment of Postmenopausal Osteoporosis |
| 9-Jun-2010 |
Unigene Appoints New CEO, Ashleigh Palmer |
| 10-May-2010 |
Unigene Reports Financial Results For First Quarter 2010 |
| 28-Apr-2010 |
Unigene to Release First Quarter 2010 Results and Host Conference Call |
| 17-Mar-2010 |
Unigene Receives Additional Capital in Debt Restructuring; Begins to Revamp Management Team |
| 16-Mar-2010 |
Unigene Reports Financial Results for Fourth Quarter and Year-End 2009 |
| 10-Mar-2010 |
Unigene to Release Fiscal 2009 Results and Host Conference Call |
| 23-Dec-2009 |
Unigene Files Shelf Registration Statement |
| 17-Dec-2009 |
Unigene Announces Promising Preclinical Results in Its Obesity Peptide Program |
| 10-Dec-2009 |
Independent Advisory Committee Recommends Continuation of Phase III Oral Calcitonin Studies for Osteoporosis and Osteoarthritis |
| 9-Dec-2009 |
Unigene Announces Significant Cost Savings and Corporate Restructuring |
| 9-Nov-2009 |
Unigene Announces Financial Results for Third Quarter 2009 |
| 4-Nov-2009 |
Unigene to Release Third Quarter 2009 Results and Host Conference Call |
| 20-Oct-2009 |
Unigene Licenses Phase III Oral Calcitonin Program to Tarsa Therapeutics |
| 20-Oct-2009 |
Unigene to Host Conference Call to Discuss Phase III Oral Calcitonin Licensing Agreement with Tarsa Therapeutics |
| 2-Sep-2009 |
U.S. District Court Confirms Validity of Unigene’s Fortical(R) Patent |
| 10-Aug-2009 |
Unigene Announces Financial Results For Second Quarter 2009 |
| 4-Aug-2009 |
Unigene to Release Second Quarter 2009 Results and Host Conference Call |
| 29-May-2009 |
Unigene Draws Down Remaining $5 Million from Non-Convertible Debt Financing |
| 29-May-2009 |
Unigene’s First Site-Directed Bone Growth Patent Issues |
| 14-May-2009 |
Hot Flashes May Prompt Closer Look at Bone Health |
| 12-May-2009 |
Unigene Reports Financial Results For First Quarter 2009 |
| 5-May-2009 |
Unigene to Release First Quarter 2009 Results and Host Conference Call |
| 26-Mar-2009 |
Pedaling Toward Osteoporosis? |
| 16-Mar-2009 |
Unigene Reports Positive PTH Clinical Study Results |
| 16-Mar-2009 |
Unigene Reports Financial Results for Fourth Quarter And Year-End 2008 |
| 12-Mar-2009 |
Webcast Alert: Fourth Quarter 2008 Earnings Conference Call |
| 9-Mar-2009 |
Unigene to Release Year-End Results and Host Conference Call |
| 2-Feb-2009 |
Unigene Clinical Study Suggests Novel Treatment Regimen for Osteoporosis |
| 20-Jan-2009 |
Unigene Reports Positive Results on a Novel Peptide for Reducing Food Consumption |
| 7-Jan-2009 |
Unigene Laboratories, Inc. Announces Addition of Independent Director to Company Board |
| 8-Dec-2008 |
Unigene Announces Preliminary Injunction Entered in Patent Infringement Lawsuit |
| 14-Nov-2008 |
Unigene Laboratories, Inc. Joins Scrip World’s Biotechnology Top Fifty |
| 13-Nov-2008 |
FEATURE/Osteoporosis Drugs May Prevent Future Bone Growth |
| 13-Nov-2008 |
[video] Wall St. Network’s 3-Minute Press Show Features Executive Interviews and Highlights Recent Press for the Following: EVOL, MRGE, BTN, ITRO, UGNE, FNIX, NVSR, UDSG, HRAL, BNPD |
| 13-Nov-2008 |
Osteoporosis Drugs May Prevent Future Bone Growth |
| 10-Nov-2008 |
Unigene Announces Financial Results For Third Quarter 2008 |
| 5-Nov-2008 |
Unigene to Release Third Quarter Financial Results and Host Conference Call |
| 6-Oct-2008 |
Unigene Initiates Phase I Clinical Study for Oral PTH |
| 30-Sep-2008 |
Unigene Enters into Agreement for $20 Million Non-Convertible Debt Financing |
| 18-Sep-2008 |
Unigene Reports on Design of Clinical Program for Oral Calcitonin |
| 12-Aug-2008 |
FEATURE/Olympian Bone Health for China |
| 11-Aug-2008 |
Olympian Bone Health for China |
| 11-Aug-2008 |
Unigene Announces Financial Results For Second Quarter 2008 |
| 6-Aug-2008 |
Unigene to Release Second Quarter Financial Results and Host Conference Call |
| 10-Jul-2008 |
Unigene CEO Discusses Value of Peptides and Company’s Technologies in Two Leading Pharmaceutical Trade Publications |
| 12-May-2008 |
China Joint Venture Partner to Invest $2 Million in Unigene |
| 12-May-2008 |
Unigene Announces Financial Results For First Quarter 2008 |
| 8-May-2008 |
Unigene to Release First Quarter 2008 Results and Host Conference Call |
| 29-Apr-2008 |
FDA Approves Second Improvement to Unigene’s Calcitonin Manufacturing Process |
| 23-Apr-2008 |
Unigene Joint Venture Breaks Ground for Global Biotechnology Park in China |
| 17-Mar-2008 |
Unigene Announces Financial Results for Fourth Quarter and Year-End 2007 |
| 13-Mar-2008 |
Unigene Restates Policy on Analyst Reports |
| 12-Mar-2008 |
Unigene to Release Year End Results and Host Conference Call on March 18, 2008 |
| 12-Mar-2008 |
Unigene Successfully Completes Phase I/II Clinical Study for Oral Calcitonin |
| 12-Mar-2008 |
Unigene Reports Transfer of Beneficial Ownership of Shares by Management |
| 10-Mar-2008 |
Boning up on New Osteoporosis Risk Guidelines |
| 10-Mar-2008 |
FEATURE/Boning up on New Osteoporosis Risk Guidelines |
| 13-Feb-2008 |
Unigene to Present at the 20th Annual Roth Capital Partners Growth Stock Conference |
| 12-Feb-2008 |
Unigene Announces Publication of Initial Results of Site-Directed Bone Growth Studies |
| 11-Feb-2008 |
Unigene Initiates Phase I/II Clinical Study for Oral Calcitonin |
| 17-Jan-2008 |
FDA Approves Improvement to Unigene’s Calcitonin Manufacturing Process |
| 8-Jan-2008 |
Unigene and Shijiazhuang Pharmaceutical Group to Expand Chinese Joint Venture |
